Level C· Early human research exploring benefitsProspective StudyPubMed

Evaluation of the Safety and Efficacy of the Therapeutic Potential of Adipose-Derived Stem Cells Injected in the Cerebral Ischemic Penumbra.

Gómez-Pinedo U., Sanchez-Rojas L., Benito-Martin MS., Lendinez C., León-Espinosa G., Rascón-Ramirez FJ.

Prospective Study on Stroke Research, published in J Stroke Cerebrovasc Dis (2018) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
J Stroke Cerebrovasc Dis (2018)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
30029838
DOI
10.1016/j.jstrokecerebrovasdis.2018.05.001
Citations
8

Abstract (original English)

Introduction Stroke represents an attractive target for cell therapy. Although different types of cells have been employed in animal models with variable results, the human adipose-derived stem cells (hASCs) have demonstrated favorable characteristics in the treatment of diseases with inflammatory substrate, but experience in their intracerebral administration is lacking. The purpose of this study is to evaluate the effect and safety of the intracerebral application of hASCs in a stroke model. Methods A first group of Athymic Nude mice after stroke received a stereotactic injection of hASCs at a concentration of 4 × 10 4 /µL at the penumbra area, a second group without stroke received the same cell concentration, and a third group had only stroke and no cells. After 7, 15, and 30 days, the animals underwent fluorodeoxyglucose-positron emission tomography and magnetic resonance imaging; subsequently, they were sacrificed for histological evaluation (HuNu, GFAP, IBA-1, Ki67, DCX) of the penumbra area and ipsilateral subventricular zone (iSVZ). Results The in vitro studies found no alterations in the molecular karyotype, clonogenic capacity, and expression of 62 kDa transcription factor and telomerase. Animals implanted with cells showed no adverse events. The implanted cells showed no evidence of proliferation or differentiation. However, there was an increase of capillaries, les

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
Adipose TissueAnimalsBrainBrain IschemiaCell ProliferationDisease Models, AnimalDoublecortin ProteinGliosisHumansMale

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research